Judge OKs $486M Celebrex, Bextra Securities MDL Deal

Law360, New York (September 19, 2016, 3:25 PM EDT) -- A New York federal judge on Friday preliminarily approved Pfizer Inc.'s $486 million settlement resolving long-running multidistrict litigation accusing the company of misleading investors about the alleged risks of its pain treatments Celebrex and Bextra and set a final approval hearing for Dec. 21.

U.S. District Judge Laura Taylor Swain also said that in light of the extensive effort to notify potential class members as part of the class certification process, it's unnecessary to give people further opportunity to exclude themselves from the class. Furthermore, anyone opting out would appear to be time-barred from suing Pfizer for the claims released by...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!